Jim Simons’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $134K | Buy |
220,800
+44,100
| +25% | +$33.2K | ﹤0.01% | 2984 |
|
|
2025
Q4 | $136K | Sell |
176,700
-99,161
| -36% | -$89.4K | ﹤0.01% | 2956 |
|
|
2025
Q3 | $279K | Buy |
275,861
+170,174
| +161% | +$200K | ﹤0.01% | 3029 |
|
|
2025
Q2 | $141K | Buy |
+105,687
| New | +$144K | ﹤0.01% | 3243 |
|
|
2025
Q1 | – | Sell |
-100,000
| Closed | -$163K | – | 3748 |
|
|
2024
Q4 | $163K | Buy |
100,000
+76,800
| +331% | +$203K | ﹤0.01% | 3216 |
|
|
2024
Q3 | $88.6K | Buy |
+23,200
| New | +$77.4K | ﹤0.01% | 3276 |
|
|
2024
Q2 | – | Sell |
-354,800
| Closed | -$1.41M | – | 3849 |
|
|
2024
Q1 | $1.41M | Buy |
354,800
+234,100
| +194% | +$1.21M | ﹤0.01% | 2256 |
|
|
2023
Q4 | $600K | Buy |
+120,700
| New | +$600K | ﹤0.01% | 2701 |
|
|
2023
Q3 | – | Sell |
-22,862
| Closed | -$115K | – | 3981 |
|
|
2023
Q2 | $115K | Sell |
22,862
-342,875
| -94% | -$2.25M | ﹤0.01% | 3442 |
|
|
2023
Q1 | $2.25M | Buy |
365,737
+118,400
| +48% | +$969K | ﹤0.01% | 1961 |
|
|
2022
Q4 | $3.27M | Sell |
247,337
-74,987
| -23% | -$529K | ﹤0.01% | 1761 |
|
|
2022
Q3 | $957K | Sell |
322,324
-68,713
| -18% | -$292K | ﹤0.01% | 2525 |
|
|
2022
Q2 | $1.43M | Sell |
391,037
-274,000
| -41% | -$1.3M | ﹤0.01% | 2453 |
|
|
2022
Q1 | $4.12M | Buy |
665,037
+220,300
| +50% | +$1.37M | ﹤0.01% | 1738 |
|
|
2021
Q4 | $3.6M | Buy |
444,737
+78,900
| +22% | +$849K | ﹤0.01% | 1738 |
|
|
2021
Q3 | $5.45M | Sell |
365,837
-89,620
| -20% | -$1.12M | 0.01% | 1417 |
|
|
2021
Q2 | $5.72M | Sell |
455,457
-212,290
| -32% | -$1.66M | 0.01% | 1553 |
|
|
2021
Q1 | $3.04M | Sell |
667,747
-160,974
| -19% | -$648K | ﹤0.01% | 1957 |
|
|
2020
Q4 | $1.77M | Buy |
828,721
+44,864
| +6% | +$98.3K | ﹤0.01% | 2194 |
|
|
2020
Q3 | $1.83M | Buy |
783,857
+161,185
| +26% | +$452K | ﹤0.01% | 2192 |
|
|
2020
Q2 | $1.25M | Buy |
622,672
+313,051
| +101% | +$349K | ﹤0.01% | 2438 |
|
|
2020
Q1 | $226K | Buy |
309,621
+189,352
| +157% | +$328K | ﹤0.01% | 3070 |
|
|
2019
Q4 | $319K | Buy |
120,269
+28,700
| +31% | +$81.8K | ﹤0.01% | 3056 |
|
|
2019
Q3 | $309K | Buy |
91,569
+13,100
| +17% | +$76.2K | ﹤0.01% | 3027 |
|
|
2019
Q2 | $470K | Buy |
78,469
+38,105
| +94% | +$249K | ﹤0.01% | 3013 |
|
|
2019
Q1 | $299K | Buy |
40,364
+12,103
| +43% | +$101K | ﹤0.01% | 3095 |
|
|
2018
Q4 | $181K | Buy |
28,261
+15,081
| +114% | +$200K | ﹤0.01% | 3155 |
|
|
2018
Q3 | $216K | Buy |
13,180
+845
| +7% | +$15.2K | ﹤0.01% | 3129 |
|
|
2018
Q2 | $254K | Buy |
12,335
+165
| +1% | +$3.44K | ﹤0.01% | 3017 |
|
|
2018
Q1 | $287K | Buy |
12,170
+3,430
| +39% | +$923K | ﹤0.01% | 3092 |
|
|
2017
Q4 | $1.64M | Buy |
8,740
+105
| +1% | +$21.1K | ﹤0.01% | 2454 |
|
|
2017
Q3 | $1.85M | Buy |
8,635
+5,595
| +184% | +$1.16M | ﹤0.01% | 2329 |
|
|
2017
Q2 | $624K | Buy |
3,040
+1,410
| +87% | +$278K | ﹤0.01% | 2705 |
|
|
2017
Q1 | $297K | Buy |
+1,630
| New | +$323K | ﹤0.01% | 2909 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Jim Simons's PDSB Position: Q1 2026 in Review
Jim Simons increased its PDS Biotechnology (PDSB) stake by 25% in Q1 2026, buying an estimated $33.2K and bringing the position to 220,800 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #2984.
Jim Simons first reported a position in PDSB in Q1 2017 and has held it in 34 quarters since. The position peaked at $5.72M in Q2 2021. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Jim Simons held 220,800 shares of PDS Biotechnology worth $134K as of Q1 2026.
- Jim Simons bought 44,100 PDS Biotechnology shares in Q1 2026, an estimated $33.2K.
- PDS Biotechnology made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2984 holding.
- Jim Simons first reported a position in PDS Biotechnology in Q1 2017 and has held it in 34 quarters since.
- Jim Simons's PDS Biotechnology position peaked at $5.72M in Q2 2021.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.